Possibilities of using lactobacilli metabolites for the treatment and prevention of bacterial vaginosis

Abstract

Bacterial vaginosis is one of the most common reasons for pathological discharge from the genital tract in women of reproductive age, which, among other things, is characterized by a high recurrence rate after standard antibacterial treatment. To date, issues related to the prevention and treatment of bacterial vaginosis have remained relevant and unresolved. This review article discusses the feasibility of using lactobacilli metabolites in the treatment and prevention of bacterial vaginosis, taking into account the data accumulated. The use of lactic acid as an additional second stage of bacterial vaginosis treatment can be considered as a way to improve the effectiveness of therapy and patient adherence to treatment, as well as to reduce the likelihood of recurrences.

Keywords

lactic acid / hydrogen peroxide / bacterial vaginosis

References

[1] Kenyon CR, Buyze J, Klebanoff M, et al. Association between bacterial vaginosis and partner concurrency: a longitudinal study. Sex Transm Infect. 2018;94(1):75–77. doi: 10.1136/sextrans-2016-052652

[2] Kenyon C.R., Buyze J., Klebanoff M., et al. Association between bacterial vaginosis and partner concurrency: a longitudinal study // Sex Transm Infect. 2018. Vol. 94, N. 1. P. 75–77. doi: 10.1136/sextrans-2016-052652

[3] Brotman RM, Klebanoff MA, Nansel TR, et al. A longitudinal study of vaginal douching and bacterial vaginosis – a marginal structural modeling analysis. Am J Epidemiol. 2008;168(2):188–196. doi: 10.1093/aje/kwn103

[4] Brotman R.M., Klebanoff M.A., Nansel T.R., et al. A longitudinal study of vaginal douching and bacterial vaginosis – a marginal structural modeling analysis // Am J Epidemiol. 2008. Vol. 168, N. 2. P. 188–196. doi: 10.1093/aje/kwn103

[5] Madden T, Grentzer JM, Secura GM, et al. Risk of bacterial vaginosis in users of the intrauterine device: a longitudinal study. Sex Transm Dis. 2012;39(3):217–222. doi: 10.1097/OLQ.0b013e31823e68fe

[6] Madden T., Grentzer J.M., Secura G.M., et al. Risk of bacterial vaginosis in users of the intrauterine device: a longitudinal study // Sex Transm Dis. 2012. Vol. 39, N. 3. P. 217–222. doi: 10.1097/OLQ.0b013e31823e68fe

[7] Brotman RM, He X, Gajer P, et al. Association between cigarette smoking and the vaginal microbiota: a pilot study. BMC Infect Dis. 2014;14:471. doi: 10.1186/1471-2334-14-471

[8] Brotman R.M., He X., Gajer P., et al. Association between cigarette smoking and the vaginal microbiota: a pilot study // BMC Infect Dis. 2014. Vol. 14. P. 471. doi: 10.1186/1471-2334-14-471

[9] Boskey ER, Cone RA, Whaley KJ, et al. Origins of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source. Hum Reprod. 2001;16(9):1809–1813. doi: 10.1093/humrep/16.9.1809

[10] Boskey E.R., Cone R.A., Whaley K.J., et al. Origins of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source // Hum Reprod. 2001. Vol. 16, N. 9. P. 1809–1813. doi: 10.1093/humrep/16.9.1809

[11] Amabebe E, Anumba DOC. The vaginal microenvironment: the physiologic role of Lactobacilli. Front Med. 2018;5:181. doi: 10.3389/fmed.2018.00181

[12] Amabebe E., Anumba D.O.C. The vaginal microenvironment: the physiologic role of Lactobacilli // Front Med. 2018. Vol. 5. P. 181. doi: 10.3389/fmed.2018.00181

[13] Tyssen D, Wang YY, Hayward JA, et al. Anti-HIV-1 activity of lactic acid in human cervicovaginal fluid. mSphere. 2018;3(4). doi: 10.1128/mSphere.00055-18

[14] Tyssen D., Wang Y.Y., Hayward J.A., et al. Anti-HIV-1 activity of lactic acid in human cervicovaginal fluid // mSphere. 2018. Vol. 3, N. 4. doi: 10.1128/mSphere.00055-18

[15] Conti C, Malacrino C, Mastromarino P. Inhibition of herpes simplex virus type 2 by vaginal lactobacilli. J Physiol Pharmacol. 2009;60(Suppl 6):19–26.

[16] Conti C., Malacrino C., Mastromarino P. Inhibition of herpes simplex virus type 2 by vaginal lactobacilli // J Physiol Pharmacol. 2009. Vol. 60, N. 6. P. 19–26.

[17] Gong Z, Luna Y, Yu P, et al. Lactobacilli inactivate Chlamydia trachomatis through lactic acid but not H2O2. PLoS One. 2014;9(9). doi: 10.1371/journal.pone.0107758

[18] Gong Z., Luna Y., Yu P., et al. Lactobacilli inactivate Chlamydia trachomatis through lactic acid but not H2O2 // PLoS One. 2014. Vol. 9, N. 9. doi: 10.1371/journal.pone.0107758

[19] Foschi C, Salvo M, Cevenini R, et al. Vaginal lactobacilli reduce neisseria gonorrhoeae viability through multiple strategies: an in vitro study. Front Cell Infect Microbiol. 2017;7:502. doi: 10.3389/fcimb.2017.00502

[20] Foschi C., Salvo M., Cevenini R., et al. Vaginal lactobacilli reduce neisseria gonorrhoeae viability through multiple strategies: an in vitro study // Front Cell Infect Microbiol. 2017. Vol. 7. P. 502. doi: 10.3389/fcimb.2017.00502

[21] Hearps AC, Tyssen D, Srbinovski D, et al. Vaginal lactic acid elicits an anti-inflammatory response from human cervicovaginal epithelial cells and inhibits production of pro-inflammatory mediators associated with HIV acquisition. Mucosal Immunol. 2017;10(6):1480–1490. doi: 10.1038/mi.2017.27

[22] Hearps A.C., Tyssen D., Srbinovski D., et al. Vaginal lactic acid elicits an anti-inflammatory response from human cervicovaginal epithelial cells and inhibits production of pro-inflammatory mediators associated with HIV acquisition // Mucosal Immunol. 2017. Vol. 10, N. 6. P. 1480–1490. doi: 10.1038/mi.2017.27

[23] O’Hanlon DE, Moench TR, Cone RA. In vaginal fluid, bacteria associated with bacterial vaginosis can be suppressed with lactic acid but not hydrogen peroxide. BMC Infect Dis. 2011;11:200. doi: 10.1186/1471-2334-11-200

[24] O’Hanlon D.E., Moench T.R., Cone R.A. In vaginal fluid, bacteria associated with bacterial vaginosis can be suppressed with lactic acid but not hydrogen peroxide // BMC Infect Dis. 2011. Vol. 11. P. 200. doi: 10.1186/1471-2334-11-200

[25] Miko E, Barakonyi A. The role of hydrogen-peroxide (H2O2) produced by vaginal microbiota in female reproductive health. Antioxidants. 2023;12(5):1055. doi: 10.3390/antiox12051055

[26] Miko E., Barakonyi A. The role of hydrogen-peroxide (H2O2) produced by vaginal microbiota in female reproductive health // Antioxidants. 2023. Vol. 12, N. 5. P. 1055. doi: 10.3390/antiox12051055

[27] Chaithongwongwatthana S, Limpongsanurak S, Sitthi-Amorn C. Single hydrogen peroxide vaginal douching versus single-dose oral metronidazole for the treatment of bacterial vaginosis: a randomized controlled trial. J Med Assoc Thai. 2003;86( Suppl 2):S379–S384.

[28] Chaithongwongwatthana S., Limpongsanurak S., Sitthi-Amorn C. Single hydrogen peroxide vaginal douching versus single-dose oral metronidazole for the treatment of bacterial vaginosis: a randomized controlled trial // J Med Assoc Thai. 2003. Vol. 86, N. 2. P. S379–S384.

[29] Ross JDC, Brittain C, Anstey Watkins J, et al. Intravaginal lactic acid gel versus oral metronidazole for treating women with recurrent bacterial vaginosis: the VITA randomised controlled trial. BMC Womens Health. 2023;23(1):241. doi: 10.1186/s12905-023-02303-5

[30] Ross J.D.C., Brittain C., Anstey Watkins J., et al. Intravaginal lactic acid gel versus oral metronidazole for treating women with recurrent bacterial vaginosis: the VITA randomised controlled trial // BMC Womens Health. 2023. Vol. 23, N. 1. P. 241. doi: 10.1186/s12905-023-02303-5

[31] Mendling W, Shazly MAE, Zhang L. The Role of lactic acid in the management of bacterial vaginosis: a systematic literature review. Future Pharmacology. 2022;2(3):198–213. doi: 10.3390/futurepharmacol2030014

[32] Mendling W., Shazly M.A.E., Zhang L. The role of lactic acid in the management of bacterial vaginosis: a systematic literature review // Future Pharmacology. 2022. Vol. 2, N. 3. P. 198–213. doi: 10.3390/futurepharmacol2030014

RIGHTS & PERMISSIONS

Eсо-Vector